Belite completes rolling submission for tinlarebant for the treatment of Stargardt disease type 1.
Belite Bio announces it has completed its rolling New Drug Application submission to the U.S. FDA for tinlarebant for the treatment of Stargardt disease type 1.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.